Montreal CRO MHICC Chooses LifeSphere® Safety to Process Adverse Event Cases as Part of Its Expansion into Post-Market Services
Montreal Health Innovations Coordinating Center (MHICC), a fast-growing contract research organization, believes LifeSphere’s innovative use of automation and Generative AI is aligned with its pharmacovigilance plans
Boston, Massachusetts, USA – July 16, 2024 – ArisGlobal, a technology company at the forefront of life sciences and creator of LifeSphere®, today announced that Canadian contract research organization (CRO), Montreal Health Innovations Coordinating Center (MHICC) has selected LifeSphere® MultiVigilance and Reporting & Analytics to advance its solutions.
MHICC makes this decision as part of plans to expand into safety services for its biopharma clients. This new focus will complement the service provider’s existing pre-market clinical activities, provided to multinational pharma and biotech organizations.
Via ArisGlobal’s CRO partnership model, MHICC will integrate LifeSphere MultiVigilance, an advanced end-to-end automation-based safety platform, into its planned pharmacovigilance activities, enabling the company to bring new safety services to market.
MHICC leveraged ArisGlobal’s deep domain expertise to determine MultiVigilance and Reporting & Analytics as the best solutions for its clients. Both MultiVigilance and Reporting & Analytics harness the latest technologies including next-generation AI to ensure maximum efficiency and differentiation in the proposition offered to MHICC’s clients.
Commenting on MHICC’s decision to harness LifeSphere to deliver its new services, Executive Director Sophie Tanguay, said: “ArisGlobal’s innovative application of advanced automation and the company’s willingness to tailor the perfect solution for our requirements, made LifeSphere the right choice for this strategic expansion of our services. Instead of feeling we had to adopt and use features we wouldn’t need as a CRO with specific needs, ArisGlobal has worked with us very closely to tailor the ideal combination of capabilities, which we can access via the Cloud. That flexibility, along with the richness of the platform, made LifeSphere the clear choice.”
MHICC came into being when professionals from varied disciplines joined forces on a cardiology clinical research project funded by the Canadian Institute of Health Research. Up to now, the CRO has both supported smaller academic studies and performed comprehensive point-to-point studies for multinational pharmaceuticals. Steady growth has allowed MHICC to branch out of its original cardiology therapeutic area and into fields such as oncology, neurology, gastroenterology and endocrinology, while strategic partnerships have opened the global market to the ambitious CRO.
About ArisGlobal
ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn or visit www.arisglobal.com.
About MHICC
MHICC is a full service academic clinical research organization (CRO), servicing the academic community and the pharmaceutical, biotechnology, nutritional and medical device industries. The MHICC’s flexible, dynamic and fully integrated "a la carte" services support Phase I to IV clinical projects, from protocol conception, data management, biostatistics, to delivery of clinical study reports. To learn more about the MHICC, visit www.mhicc.org or connect here on LinkedIn.
Media Contact
Carina Birt, Sarum Life Sciences on behalf of ArisGlobal
carina@sarumlifesciences.com
+44 7970 006624
